Navigation Links
Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique

LOD, Israel, Sept. 25 /PRNewswire/ -- Glycominds Ltd., a biodiagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today that has entered the Biomolecular Photonic (BMP) Consortium. BMP is a new consortium funded by the Government of Israel to improve in-vivo imaging diagnostics for Crohn's disease (CD) and colorectal cancer. The BMP consortium was approved for three years and was granted $4 million for its first year.

"We are very pleased to join the BMP consortium," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP, R&D. "Combining biomarker experience with our glycan technology will promote the in-vivo imaging technology developed in Israel. Our collaboration with companies such as Given Imaging (Nasdaq: GIVN) will accelerate the new concept of combining in vitro-in vivo assays towards sensitive biomolecular imaging techniques to enable a more rapid, accurate and earlier diagnosis of Crohn's disease and colorectal cancer."

"Glycominds' glycan biomarker technology stands out as innovative and unique, providing the consortium with proven biomarkers for Crohn's disease and a great opportunity for diagnosing colorectal cancer," stated Dr. Elisha Rabinovitz, the head of the Israeli consortium and Given Imaging CSO. "I believe that glycan technology has the potential to enhance CD diagnosis and early detection of cancers. Glycominds is clearly pioneering the implementation of glycan biomarkers."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Other pipeline products of Glycominds' include blood tests for the prediction of recurrent pregnancy losscaused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers.

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

The Ruth Group

Sara Ephraim (investors)

Phone: 646-536-7002

Janine McCargo (media)

Phone: 646-536-7033

SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):